Modifiable clinical and lifestyle factors are associated with elevated alanine aminotransferase levels in newly diagnosed type 2 diabetes patients: Results from the nationwide DD2 study

Diabetes/Metabolism Research and Reviews

Volumn 30, Issue 8, 2014, Pages 707-715

  Mor, Anil ^a   Svensson, Elisabeth ^a   Rungby, Jørgen ^a,b   Ulrichsen, Sinna Pilgaard ^a   Berencsi, Klara ^a   Nielsen, Jens Steen ^c   Stidsen, Jacob Volmer ^c   Friborg, Søren ^c   Brandslund, Ivan ^d   Christiansen, Jens Sandahl ^a   Beck Nielsen, Henning ^c   Sørensen, Henrik Toft ^a   Thomsen, Reimar Wernich ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d LILLEBAELT HOSPITAL   (Denmark)

Author keywords

Alanine aminotransferase; DD2 study; Lifestyle factors; Markers; Non alcoholic fatty liver disease; Type 2 diabetes mellitus

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; C PEPTIDE; GLUCOSE; INSULIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ANTIHYPERTENSIVE THERAPY; ARTICLE; COMORBIDITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN TREATMENT; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PHOTOMETRY; PHYSICAL ACTIVITY; PREVALENCE; RISK ASSESSMENT; ADVERSE EFFECTS; BLOOD; COHORT ANALYSIS; COMPLICATION; CROSS-SECTIONAL STUDY; DENMARK; DRINKING BEHAVIOR; NON-ALCOHOLIC FATTY LIVER DISEASE; POISSON DISTRIBUTION; SEDENTARY LIFESTYLE; SEX DIFFERENCE; STATISTICAL MODEL; WEIGHT GAIN; YOUNG ADULT;

ADULT; ALANINE TRANSAMINASE; ALCOHOL DRINKING; BIOLOGICAL MARKERS; C-PEPTIDE; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DENMARK; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LINEAR MODELS; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; POISSON DISTRIBUTION; PREVALENCE; SEDENTARY LIFESTYLE; SEX FACTORS; WEIGHT GAIN; YOUNG ADULT;

EID: 84910651912     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2539     Document Type: Article

References (42)

1. Angulo P. Medical progress - nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
2. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013; 58: 593-608.
3. Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabet Med 2007; 24: 1-6.
4. Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109(3): 433-438.
5. Souza MR, Diniz Mde F, Medeiros-Filho JE, Araujo MS. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol 2012; 49: 89-96.
6. Schindhelm RK, Dekker JM, Nijpels G, et al. Alanine aminotransferase and the 6-year risk of the metabolic syndrome in Caucasian men and women: the Hoorn Study. Diabet Med 2007; 24: 430-435.
7. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB Jr, Haffner SM. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 2005; 54: 3140-3147.
8. Goessling W, Massaro JM, Vasan RS, D'Agostino RBS, Ellison RC, Fox CS. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 2008; 135: 1935-1944.
9. Adams LA, Harmsen S, St Sauver JL, et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol 2010; 105: 1567-1573.
10. Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev 2010; 11: 430-445.
11. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52.
12. Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004; 2: 262-265.
13. Hossain N, Afendy A, Stepanova M, et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1224-1229.
14. Cusi K. Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2009; 16: 141-149.
15. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960-967.
16. Yu AS, Keeffe EB. Elevated AST or ALT to nonalcoholic fatty liver disease: accurate predictor of disease prevalence? Am J Gastroenterol 2003; 98: 955-956.
17. Pearce SG, Thosani NC, Pan JJ. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomarker Res 2013; 1(1). doi:10.1186/2050-7771-1-7.
18. Forlani G, Di Bonito P, Mannucci E, et al. Prevalence of elevated liver enzymes in type 2 diabetes mellitus and its association with the metabolic syndrome. J Endocrinol Invest 2008; 31: 146-152.
19. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14.
20. Mendez-Sanchez N, Villa AR, Chavez-Tapia NC, et al. Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. Ann Hepatol 2005; 4: 52-55.
21. Thomsen RW, Friborg S, Nielsen JS, Schroll H, Johnsen SP. The Danish Centre for Strategic Research in Type 2 Diabetes (DD2): organization of diabetes care in Denmark and supplementary data sources for data collection among DD2 study participants. Clin Epidemiol 2012; 4: 15-19.
22. Nielsen JS, Thomsen RW, Steffensen C, Christiansen JS. The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) study: implementation of a nationwide patient enrollment system. Clin Epidemiol 2012; 4: 27-36.
23. Thomsen RW, Nielsen JS, Ulrichsen SP, Pedersen L, Hansen AM, Nilsson T. The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) study: collection of baseline data from the first 580 patients. Clin Epidemiol 2012; 4: 43-48.
24. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011; 39: 30-33.
25. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. a valuable source of data for modern health sciences. Dan Med Bull 1999; 46(3): 263-268.
26. Johannesdottir SA, Horvath-Puho E, Ehrenstein V, Schmidt M, Pedersen L, Sorensen HT. Existing data sources for clinical epidemiology: The Danish National Database of Reimbursed Prescriptions. Clin Epidemiol 2012; 4: 303-313.
27. Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 2006; 53: 441-449.
28. Klauke R, Schmidt E, Lorentz K. Recommendations for carrying out standard ECCLS procedures (1988) for the catalytic concentrations of creatine kinase, aspartate aminotransferase, alanine aminotransferase and gamma-glutamyltransferase at 37 degrees C. Standardization Committee of the German Society for Clinical Chemistry, Enzyme Working Group of the German Society for Clinical Chemistry. Eur J Clin Chem Clin Biochem 1993; 31(12): 901-909.
29. Leino A, Impivaara O, Irjala K, Maki J, Peltola O, Jarvisalo J. Health-based reference intervals for ALT, ASAT and GT in serum, measured according to the recommendations of the European Committee for Clinical Laboratory Standards (ECCLS). Scand J Clin Lab Invest 1995; 55(3): 243-250.
30. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
31. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
32. Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol 2011; 11: 83.
33. Kornum JB, Thomsen RW, Riis A, Lervang HH, Schonheyder HC, Sorensen HT. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care 2008; 31: 1541-1545.
34. Steffensen FH, Sorensen HT, Brock A, Vilstrup H, Lauritzen T. Alcohol consumption and serum liver-derived enzymes in a Danish population aged 30-50 years. Int J Epidemiol 1997; 26: 92-99.
35. Saligram S, Williams EJ, Masding MG. Raised liver enzymes in newly diagnosed type 2 diabetes are associated with weight and lipids, but not glycaemic control. Indian J Endocrinol Metab 2012; 16: 1012-1014.
36. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-1850.
37. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-S112.
38. Sanyal AJ, American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-1725.
39. Feldstein AE, Werneburg NW, Canbay A, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004; 40: 185-194.
40. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752-1761.
41. Harrison SA. Liver disease in patients with diabetes mellitus. J Clin Gastroenterol 2006; 40: 68-76.
42. Nomura K, Yano E, Shinozaki T, Tagawa K. Efficacy and effectiveness of liver screening program to detect fatty liver in the periodic health check-ups. J Occup Health 2004; 46: 423-428.